Skip to main content
Premium Trial:

Request an Annual Quote

Additional PPOs to Cover Signal Genetics Multiple Myeloma Test

NEW YORK (GenomeWeb) – Signal Genetics today announced agreements with three preferred provider organizations to cover the firm's multiple myeloma prognostic molecular diagnostic test.

The deals are with Stratose, USA Managed Care Organization, and Evolutions Health Systems, and provide covered access to Signal Genetics' MyPRS test to more than 21 million patients in the US. In total, more than 93 million patients in the US are covered for the test by payors, the Carlsbad, California-based company said.

MyPRS is microarray-based prognostic test for multiple myeloma and stratifies patients into molecular subtypes and into high- and low-risk categories using gene expression profiling. Signal Genetics reached an agreement during the summer with America's Choice Provider Network to provide coverage of the assay.

The Scan

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.

Sequencing Analysis Examines Gene Regulatory Networks of Honeybee Soldier, Forager Brains

Researchers in Nature Ecology & Evolution find gene regulatory network differences between soldiers and foragers, suggesting bees can take on either role.

Analysis of Ashkenazi Jewish Cohort Uncovers New Genetic Loci Linked to Alzheimer's Disease

The study in Alzheimer's & Dementia highlighted known genes, but also novel ones with biological ties to Alzheimer's disease.

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.